nodes	percent_of_prediction	percent_of_DWPC	metapath
Dantrolene—CYP3A4—breast cancer	0.255	1	CbGaD
Dantrolene—CYP3A4—Exemestane—breast cancer	0.0523	0.133	CbGbCtD
Dantrolene—CYP3A4—Letrozole—breast cancer	0.0445	0.113	CbGbCtD
Dantrolene—CYP3A4—Anastrozole—breast cancer	0.0396	0.101	CbGbCtD
Dantrolene—CYP3A4—Toremifene—breast cancer	0.0362	0.0921	CbGbCtD
Dantrolene—CYP3A4—Fulvestrant—breast cancer	0.0337	0.0856	CbGbCtD
Dantrolene—CYP3A4—Thiotepa—breast cancer	0.03	0.0763	CbGbCtD
Dantrolene—CYP3A4—Ixabepilone—breast cancer	0.0275	0.0698	CbGbCtD
Dantrolene—CYP3A4—Lapatinib—breast cancer	0.0264	0.0672	CbGbCtD
Dantrolene—CYP3A4—Raloxifene—breast cancer	0.02	0.0509	CbGbCtD
Dantrolene—CYP3A4—Vinorelbine—breast cancer	0.0147	0.0373	CbGbCtD
Dantrolene—CYP3A4—Tamoxifen—breast cancer	0.0132	0.0336	CbGbCtD
Dantrolene—CYP3A4—Mitoxantrone—breast cancer	0.0129	0.0328	CbGbCtD
Dantrolene—CYP3A4—Paclitaxel—breast cancer	0.0103	0.0262	CbGbCtD
Dantrolene—CYP3A4—Irinotecan—breast cancer	0.0102	0.0258	CbGbCtD
Dantrolene—CYP3A4—Vinblastine—breast cancer	0.00904	0.023	CbGbCtD
Dantrolene—CYP3A4—Docetaxel—breast cancer	0.00745	0.0189	CbGbCtD
Dantrolene—RYR1—nipple—breast cancer	0.00592	0.131	CbGeAlD
Dantrolene—CYP3A4—Doxorubicin—breast cancer	0.00555	0.0141	CbGbCtD
Dantrolene—RYR3—endometrium—breast cancer	0.00498	0.11	CbGeAlD
Dantrolene—RYR3—uterus—breast cancer	0.00459	0.101	CbGeAlD
Dantrolene—RYR3—pituitary gland—breast cancer	0.00451	0.0997	CbGeAlD
Dantrolene—RYR3—adipose tissue—breast cancer	0.00449	0.0992	CbGeAlD
Dantrolene—RYR3—female reproductive system—breast cancer	0.00413	0.0912	CbGeAlD
Dantrolene—RYR3—adrenal gland—breast cancer	0.00403	0.089	CbGeAlD
Dantrolene—RYR1—uterus—breast cancer	0.00329	0.0728	CbGeAlD
Dantrolene—RYR1—female reproductive system—breast cancer	0.00296	0.0654	CbGeAlD
Dantrolene—RYR1—adrenal gland—breast cancer	0.00289	0.0639	CbGeAlD
Dantrolene—RYR1—endocrine gland—breast cancer	0.00251	0.0554	CbGeAlD
Dantrolene—Nitrofurantoin—ABCG2—breast cancer	0.00184	0.863	CrCbGaD
Dantrolene—RYR1—Transmembrane transport of small molecules—SLC4A7—breast cancer	0.000593	0.00818	CbGpPWpGaD
Dantrolene—RYR3—Transmembrane transport of small molecules—SLC2A5—breast cancer	0.000586	0.0081	CbGpPWpGaD
Dantrolene—RYR3—Transmembrane transport of small molecules—SLCO1B1—breast cancer	0.000586	0.0081	CbGpPWpGaD
Dantrolene—RYR3—Myometrial Relaxation and Contraction Pathways—ITPR1—breast cancer	0.000574	0.00793	CbGpPWpGaD
Dantrolene—RYR1—Myometrial Relaxation and Contraction Pathways—CALCA—breast cancer	0.000534	0.00738	CbGpPWpGaD
Dantrolene—CYP3A4—Drug Induction of Bile Acid Pathway—SLCO1B1—breast cancer	0.000522	0.00722	CbGpPWpGaD
Dantrolene—CYP3A4—female reproductive system—breast cancer	0.000515	0.0114	CbGeAlD
Dantrolene—RYR3—Transmembrane transport of small molecules—SLC39A6—breast cancer	0.000505	0.00697	CbGpPWpGaD
Dantrolene—RYR1—Transmembrane transport of small molecules—SLC39A7—breast cancer	0.000491	0.00678	CbGpPWpGaD
Dantrolene—RYR1—Transmembrane transport of small molecules—COX11—breast cancer	0.000491	0.00678	CbGpPWpGaD
Dantrolene—RYR3—Alzheimers Disease—IL1B—breast cancer	0.000482	0.00666	CbGpPWpGaD
Dantrolene—RYR3—Alzheimers Disease—CASP3—breast cancer	0.000481	0.00665	CbGpPWpGaD
Dantrolene—RYR3—Stimuli-sensing channels—RAF1—breast cancer	0.000463	0.00639	CbGpPWpGaD
Dantrolene—RYR3—Transmembrane transport of small molecules—ATP7B—breast cancer	0.000462	0.00638	CbGpPWpGaD
Dantrolene—CYP3A4—Fatty Acid Omega Oxidation—ALDH1A1—breast cancer	0.00045	0.00622	CbGpPWpGaD
Dantrolene—RYR1—Transmembrane transport of small molecules—SLC22A18—breast cancer	0.000449	0.0062	CbGpPWpGaD
Dantrolene—CYP3A4—Irinotecan Pathway—ABCC1—breast cancer	0.000447	0.00617	CbGpPWpGaD
Dantrolene—RYR1—Calcium Regulation in the Cardiac Cell—ITPR1—breast cancer	0.000437	0.00604	CbGpPWpGaD
Dantrolene—CYP3A4—endocrine gland—breast cancer	0.000436	0.00963	CbGeAlD
Dantrolene—RYR1—Transmembrane transport of small molecules—SLC2A5—breast cancer	0.000432	0.00597	CbGpPWpGaD
Dantrolene—RYR1—Transmembrane transport of small molecules—SLCO1B1—breast cancer	0.000432	0.00597	CbGpPWpGaD
Dantrolene—RYR3—Transmembrane transport of small molecules—ABCC1—breast cancer	0.000429	0.00593	CbGpPWpGaD
Dantrolene—RYR1—Myometrial Relaxation and Contraction Pathways—ITPR1—breast cancer	0.000424	0.00585	CbGpPWpGaD
Dantrolene—CYP3A4—Codeine and Morphine Metabolism—CYP2D6—breast cancer	0.000423	0.00585	CbGpPWpGaD
Dantrolene—CYP3A4—Tryptophan metabolism—ALDH3A2—breast cancer	0.000396	0.00547	CbGpPWpGaD
Dantrolene—RYR3—Alzheimers Disease—MAPK3—breast cancer	0.000386	0.00534	CbGpPWpGaD
Dantrolene—RYR3—Myometrial Relaxation and Contraction Pathways—FOS—breast cancer	0.00038	0.00525	CbGpPWpGaD
Dantrolene—RYR1—Transmembrane transport of small molecules—SLC39A6—breast cancer	0.000372	0.00514	CbGpPWpGaD
Dantrolene—RYR3—Transmembrane transport of small molecules—TUBB3—breast cancer	0.000365	0.00504	CbGpPWpGaD
Dantrolene—RYR3—Alzheimers Disease—TNF—breast cancer	0.00035	0.00483	CbGpPWpGaD
Dantrolene—RYR1—Stimuli-sensing channels—RAF1—breast cancer	0.000341	0.00471	CbGpPWpGaD
Dantrolene—RYR1—Transmembrane transport of small molecules—ATP7B—breast cancer	0.00034	0.0047	CbGpPWpGaD
Dantrolene—CYP3A4—Liver X Receptor Pathway—FASN—breast cancer	0.000337	0.00466	CbGpPWpGaD
Dantrolene—CYP3A4—Benzo(a)pyrene metabolism—CYP1B1—breast cancer	0.000334	0.00461	CbGpPWpGaD
Dantrolene—RYR3—Myometrial Relaxation and Contraction Pathways—NOS3—breast cancer	0.000331	0.00457	CbGpPWpGaD
Dantrolene—CYP3A4—Aflatoxin B1 metabolism—GSTM1—breast cancer	0.000327	0.00451	CbGpPWpGaD
Dantrolene—CYP3A4—Estrogen metabolism—SULT1A1—breast cancer	0.000322	0.00444	CbGpPWpGaD
Dantrolene—RYR1—Transmembrane transport of small molecules—ABCC1—breast cancer	0.000316	0.00437	CbGpPWpGaD
Dantrolene—CYP3A4—Estrogen metabolism—GSTA1—breast cancer	0.000314	0.00434	CbGpPWpGaD
Dantrolene—CYP3A4—Irinotecan Pathway—ABCG2—breast cancer	0.00031	0.00428	CbGpPWpGaD
Dantrolene—RYR3—Alzheimers Disease—TP53—breast cancer	0.000309	0.00426	CbGpPWpGaD
Dantrolene—RYR3—Transmembrane transport of small molecules—SLC2A2—breast cancer	0.000304	0.00419	CbGpPWpGaD
Dantrolene—CYP3A4—Codeine and Morphine Metabolism—ABCB1—breast cancer	0.000302	0.00418	CbGpPWpGaD
Dantrolene—RYR3—Ion channel transport—RAF1—breast cancer	0.000302	0.00417	CbGpPWpGaD
Dantrolene—RYR3—Transmembrane transport of small molecules—ABCG2—breast cancer	0.000297	0.00411	CbGpPWpGaD
Dantrolene—CYP3A4—Tamoxifen metabolism—SULT1A1—breast cancer	0.000284	0.00393	CbGpPWpGaD
Dantrolene—RYR3—Myometrial Relaxation and Contraction Pathways—IL1B—breast cancer	0.000281	0.00389	CbGpPWpGaD
Dantrolene—RYR1—Myometrial Relaxation and Contraction Pathways—FOS—breast cancer	0.00028	0.00387	CbGpPWpGaD
Dantrolene—RYR3—Myometrial Relaxation and Contraction Pathways—JUN—breast cancer	0.000273	0.00377	CbGpPWpGaD
Dantrolene—RYR1—Transmembrane transport of small molecules—TUBB3—breast cancer	0.000269	0.00372	CbGpPWpGaD
Dantrolene—RYR3—Transmembrane transport of small molecules—TFRC—breast cancer	0.000265	0.00366	CbGpPWpGaD
Dantrolene—CYP3A4—Irinotecan Pathway—BCHE—breast cancer	0.000257	0.00354	CbGpPWpGaD
Dantrolene—RYR3—Transmembrane transport of small molecules—NCOA2—breast cancer	0.000255	0.00352	CbGpPWpGaD
Dantrolene—CYP3A4—Benzo(a)pyrene metabolism—CYP1A1—breast cancer	0.000253	0.0035	CbGpPWpGaD
Dantrolene—RYR1—Myometrial Relaxation and Contraction Pathways—NOS3—breast cancer	0.000244	0.00337	CbGpPWpGaD
Dantrolene—RYR3—Transmembrane transport of small molecules—SLC5A5—breast cancer	0.000243	0.00336	CbGpPWpGaD
Dantrolene—CYP3A4—Fatty Acid Omega Oxidation—CYP2D6—breast cancer	0.000243	0.00336	CbGpPWpGaD
Dantrolene—RYR3—Transmembrane transport of small molecules—SLC2A1—breast cancer	0.000235	0.00325	CbGpPWpGaD
Dantrolene—RYR1—Transmembrane transport of small molecules—SLC2A2—breast cancer	0.000224	0.00309	CbGpPWpGaD
Dantrolene—RYR1—Ion channel transport—RAF1—breast cancer	0.000222	0.00307	CbGpPWpGaD
Dantrolene—RYR1—Transmembrane transport of small molecules—ABCG2—breast cancer	0.000219	0.00303	CbGpPWpGaD
Dantrolene—RYR3—Transmembrane transport of small molecules—NCOA1—breast cancer	0.000215	0.00297	CbGpPWpGaD
Dantrolene—RYR3—Transmembrane transport of small molecules—PLG—breast cancer	0.00021	0.00289	CbGpPWpGaD
Dantrolene—RYR1—Myometrial Relaxation and Contraction Pathways—IL1B—breast cancer	0.000207	0.00286	CbGpPWpGaD
Dantrolene—CYP3A4—Constitutive Androstane Receptor Pathway—GSTA2—breast cancer	0.000206	0.00284	CbGpPWpGaD
Dantrolene—CYP3A4—Xenobiotics—CYP2D6—breast cancer	0.000203	0.00281	CbGpPWpGaD
Dantrolene—CYP3A4—Constitutive Androstane Receptor Pathway—SULT1A1—breast cancer	0.000203	0.0028	CbGpPWpGaD
Dantrolene—RYR1—Myometrial Relaxation and Contraction Pathways—JUN—breast cancer	0.000201	0.00278	CbGpPWpGaD
Dantrolene—CYP3A4—Estrogen metabolism—NQO1—breast cancer	0.0002	0.00276	CbGpPWpGaD
Dantrolene—CYP3A4—Tamoxifen metabolism—CYP2D6—breast cancer	0.000196	0.0027	CbGpPWpGaD
Dantrolene—RYR1—Transmembrane transport of small molecules—TFRC—breast cancer	0.000195	0.0027	CbGpPWpGaD
Dantrolene—CYP3A4—Tryptophan metabolism—ALDH1A1—breast cancer	0.000193	0.00267	CbGpPWpGaD
Dantrolene—RYR3—Transmembrane transport of small molecules—HMOX1—breast cancer	0.000193	0.00267	CbGpPWpGaD
Dantrolene—CYP3A4—Estrogen metabolism—CYP1B1—breast cancer	0.000192	0.00265	CbGpPWpGaD
Dantrolene—RYR1—Transmembrane transport of small molecules—NCOA2—breast cancer	0.000188	0.0026	CbGpPWpGaD
Dantrolene—RYR3—Transmembrane transport of small molecules—ABCB1—breast cancer	0.000186	0.00256	CbGpPWpGaD
Dantrolene—RYR1—Transmembrane transport of small molecules—SLC5A5—breast cancer	0.00018	0.00248	CbGpPWpGaD
Dantrolene—RYR1—Transmembrane transport of small molecules—SLC2A1—breast cancer	0.000173	0.00239	CbGpPWpGaD
Dantrolene—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—breast cancer	0.000171	0.00236	CbGpPWpGaD
Dantrolene—CYP3A4—Tamoxifen metabolism—CYP1B1—breast cancer	0.00017	0.00234	CbGpPWpGaD
Dantrolene—CYP3A4—Estrogen metabolism—COMT—breast cancer	0.000168	0.00232	CbGpPWpGaD
Dantrolene—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—breast cancer	0.000165	0.00228	CbGpPWpGaD
Dantrolene—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—breast cancer	0.000165	0.00228	CbGpPWpGaD
Dantrolene—RYR3—Myometrial Relaxation and Contraction Pathways—IL6—breast cancer	0.000165	0.00228	CbGpPWpGaD
Dantrolene—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—breast cancer	0.00016	0.00221	CbGpPWpGaD
Dantrolene—Nitrazepam—CYP3A4—breast cancer	0.000159	0.0746	CrCbGaD
Dantrolene—RYR1—Transmembrane transport of small molecules—NCOA1—breast cancer	0.000159	0.00219	CbGpPWpGaD
Dantrolene—RYR1—Transmembrane transport of small molecules—PLG—breast cancer	0.000155	0.00213	CbGpPWpGaD
Dantrolene—CYP3A4—Estrogen metabolism—GSTM1—breast cancer	0.000153	0.00212	CbGpPWpGaD
Dantrolene—CYP3A4—Estrogen metabolism—CYP1A1—breast cancer	0.000145	0.00201	CbGpPWpGaD
Dantrolene—RYR1—Transmembrane transport of small molecules—HMOX1—breast cancer	0.000143	0.00197	CbGpPWpGaD
Dantrolene—CYP3A4—Irinotecan Pathway—APC—breast cancer	0.000139	0.00192	CbGpPWpGaD
Dantrolene—CYP3A4—Constitutive Androstane Receptor Pathway—NCOA2—breast cancer	0.000137	0.00189	CbGpPWpGaD
Dantrolene—RYR1—Transmembrane transport of small molecules—ABCB1—breast cancer	0.000137	0.00189	CbGpPWpGaD
Dantrolene—CYP3A4—Xenobiotics—CYP1A1—breast cancer	0.000134	0.00185	CbGpPWpGaD
Dantrolene—Nitrazepam—ABCB1—breast cancer	0.000132	0.0621	CrCbGaD
Dantrolene—CYP3A4—Tamoxifen metabolism—CYP1A1—breast cancer	0.000129	0.00178	CbGpPWpGaD
Dantrolene—CYP3A4—Phase 1 - Functionalization of compounds—ALDH1A1—breast cancer	0.000127	0.00175	CbGpPWpGaD
Dantrolene—RYR1—Myometrial Relaxation and Contraction Pathways—IL6—breast cancer	0.000121	0.00168	CbGpPWpGaD
Dantrolene—CYP3A4—Constitutive Androstane Receptor Pathway—HSP90AA1—breast cancer	0.000119	0.00164	CbGpPWpGaD
Dantrolene—RYR3—Transmembrane transport of small molecules—ALB—breast cancer	0.000116	0.0016	CbGpPWpGaD
Dantrolene—CYP3A4—Constitutive Androstane Receptor Pathway—NCOA1—breast cancer	0.000116	0.0016	CbGpPWpGaD
Dantrolene—RYR3—Transmembrane transport of small molecules—RAF1—breast cancer	0.000105	0.00145	CbGpPWpGaD
Dantrolene—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—breast cancer	9.97e-05	0.00138	CbGpPWpGaD
Dantrolene—CYP3A4—Metapathway biotransformation—CHST9—breast cancer	9.69e-05	0.00134	CbGpPWpGaD
Dantrolene—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—breast cancer	9.5e-05	0.00131	CbGpPWpGaD
Dantrolene—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—breast cancer	9.48e-05	0.00131	CbGpPWpGaD
Dantrolene—CYP3A4—Tryptophan metabolism—CYP1B1—breast cancer	9.06e-05	0.00125	CbGpPWpGaD
Dantrolene—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP17A1—breast cancer	8.7e-05	0.0012	CbGpPWpGaD
Dantrolene—CYP3A4—Oxidation by Cytochrome P450—CYP17A1—breast cancer	8.59e-05	0.00119	CbGpPWpGaD
Dantrolene—RYR1—Transmembrane transport of small molecules—ALB—breast cancer	8.56e-05	0.00118	CbGpPWpGaD
Dantrolene—CYP3A4—Tryptophan metabolism—CYP19A1—breast cancer	8.52e-05	0.00118	CbGpPWpGaD
Dantrolene—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2D6—breast cancer	8.45e-05	0.00117	CbGpPWpGaD
Dantrolene—CYP3A4—Oxidation by Cytochrome P450—CYP2D6—breast cancer	8.34e-05	0.00115	CbGpPWpGaD
Dantrolene—CYP3A4—Cytochrome P450 - arranged by substrate type—NCOA2—breast cancer	8.29e-05	0.00115	CbGpPWpGaD
Dantrolene—Pollakiuria—Doxorubicin—breast cancer	7.89e-05	0.00034	CcSEcCtD
Dantrolene—Asthenia—Gemcitabine—breast cancer	7.86e-05	0.000339	CcSEcCtD
Dantrolene—Myalgia—Capecitabine—breast cancer	7.86e-05	0.000339	CcSEcCtD
Dantrolene—Pain—Paclitaxel—breast cancer	7.85e-05	0.000338	CcSEcCtD
Dantrolene—Constipation—Paclitaxel—breast cancer	7.85e-05	0.000338	CcSEcCtD
Dantrolene—Haematuria—Epirubicin—breast cancer	7.84e-05	0.000338	CcSEcCtD
Dantrolene—Confusional state—Docetaxel—breast cancer	7.84e-05	0.000338	CcSEcCtD
Dantrolene—Anaphylactic shock—Docetaxel—breast cancer	7.78e-05	0.000335	CcSEcCtD
Dantrolene—Discomfort—Capecitabine—breast cancer	7.76e-05	0.000335	CcSEcCtD
Dantrolene—Pruritus—Gemcitabine—breast cancer	7.75e-05	0.000334	CcSEcCtD
Dantrolene—RYR1—Transmembrane transport of small molecules—RAF1—breast cancer	7.74e-05	0.00107	CbGpPWpGaD
Dantrolene—Nausea—Thiotepa—breast cancer	7.74e-05	0.000334	CcSEcCtD
Dantrolene—Diarrhoea—Mitoxantrone—breast cancer	7.7e-05	0.000332	CcSEcCtD
Dantrolene—Diarrhoea—Irinotecan—breast cancer	7.7e-05	0.000332	CcSEcCtD
Dantrolene—Dry mouth—Capecitabine—breast cancer	7.68e-05	0.000331	CcSEcCtD
Dantrolene—Pruritus—Fluorouracil—breast cancer	7.62e-05	0.000329	CcSEcCtD
Dantrolene—Thrombocytopenia—Docetaxel—breast cancer	7.62e-05	0.000328	CcSEcCtD
Dantrolene—Drowsiness—Doxorubicin—breast cancer	7.61e-05	0.000328	CcSEcCtD
Dantrolene—Visual impairment—Methotrexate—breast cancer	7.6e-05	0.000328	CcSEcCtD
Dantrolene—Confusional state—Capecitabine—breast cancer	7.59e-05	0.000327	CcSEcCtD
Dantrolene—Tachycardia—Docetaxel—breast cancer	7.59e-05	0.000327	CcSEcCtD
Dantrolene—Feeling abnormal—Paclitaxel—breast cancer	7.56e-05	0.000326	CcSEcCtD
Dantrolene—Gastrointestinal pain—Paclitaxel—breast cancer	7.5e-05	0.000323	CcSEcCtD
Dantrolene—Diarrhoea—Gemcitabine—breast cancer	7.5e-05	0.000323	CcSEcCtD
Dantrolene—Renal failure—Doxorubicin—breast cancer	7.48e-05	0.000322	CcSEcCtD
Dantrolene—Dizziness—Irinotecan—breast cancer	7.44e-05	0.000321	CcSEcCtD
Dantrolene—Haemoglobin—Epirubicin—breast cancer	7.42e-05	0.00032	CcSEcCtD
Dantrolene—Anorexia—Docetaxel—breast cancer	7.41e-05	0.00032	CcSEcCtD
Dantrolene—Hepatitis—Epirubicin—breast cancer	7.38e-05	0.000318	CcSEcCtD
Dantrolene—Haemorrhage—Epirubicin—breast cancer	7.38e-05	0.000318	CcSEcCtD
Dantrolene—Diarrhoea—Fluorouracil—breast cancer	7.37e-05	0.000318	CcSEcCtD
Dantrolene—Thrombocytopenia—Capecitabine—breast cancer	7.37e-05	0.000318	CcSEcCtD
Dantrolene—Tachycardia—Capecitabine—breast cancer	7.35e-05	0.000317	CcSEcCtD
Dantrolene—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—breast cancer	7.32e-05	0.00101	CbGpPWpGaD
Dantrolene—Sweating—Doxorubicin—breast cancer	7.3e-05	0.000315	CcSEcCtD
Dantrolene—Urticaria—Paclitaxel—breast cancer	7.29e-05	0.000314	CcSEcCtD
Dantrolene—Hyperhidrosis—Capecitabine—breast cancer	7.28e-05	0.000314	CcSEcCtD
Dantrolene—Haematuria—Doxorubicin—breast cancer	7.26e-05	0.000313	CcSEcCtD
Dantrolene—Body temperature increased—Paclitaxel—breast cancer	7.25e-05	0.000313	CcSEcCtD
Dantrolene—Abdominal pain—Paclitaxel—breast cancer	7.25e-05	0.000313	CcSEcCtD
Dantrolene—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—breast cancer	7.23e-05	0.000998	CbGpPWpGaD
Dantrolene—Anorexia—Capecitabine—breast cancer	7.18e-05	0.000309	CcSEcCtD
Dantrolene—Vomiting—Irinotecan—breast cancer	7.15e-05	0.000308	CcSEcCtD
Dantrolene—Vomiting—Mitoxantrone—breast cancer	7.15e-05	0.000308	CcSEcCtD
Dantrolene—Dizziness—Fluorouracil—breast cancer	7.13e-05	0.000307	CcSEcCtD
Dantrolene—Visual impairment—Epirubicin—breast cancer	7.12e-05	0.000307	CcSEcCtD
Dantrolene—Rash—Mitoxantrone—breast cancer	7.09e-05	0.000306	CcSEcCtD
Dantrolene—Rash—Irinotecan—breast cancer	7.09e-05	0.000306	CcSEcCtD
Dantrolene—Dermatitis—Mitoxantrone—breast cancer	7.09e-05	0.000306	CcSEcCtD
Dantrolene—Dermatitis—Irinotecan—breast cancer	7.09e-05	0.000306	CcSEcCtD
Dantrolene—Musculoskeletal discomfort—Docetaxel—breast cancer	7.09e-05	0.000305	CcSEcCtD
Dantrolene—Chills—Methotrexate—breast cancer	7.08e-05	0.000305	CcSEcCtD
Dantrolene—CYP3A4—Phase 1 - Functionalization of compounds—CYP17A1—breast cancer	7.05e-05	0.000974	CbGpPWpGaD
Dantrolene—Headache—Mitoxantrone—breast cancer	7.05e-05	0.000304	CcSEcCtD
Dantrolene—Headache—Irinotecan—breast cancer	7.05e-05	0.000304	CcSEcCtD
Dantrolene—Insomnia—Docetaxel—breast cancer	7.03e-05	0.000303	CcSEcCtD
Dantrolene—CYP3A4—Cytochrome P450 - arranged by substrate type—NCOA1—breast cancer	6.99e-05	0.000965	CbGpPWpGaD
Dantrolene—CYP3A4—Phase 1 - Functionalization of compounds—PTGS1—breast cancer	6.98e-05	0.000964	CbGpPWpGaD
Dantrolene—Vomiting—Gemcitabine—breast cancer	6.97e-05	0.0003	CcSEcCtD
Dantrolene—Somnolence—Docetaxel—breast cancer	6.91e-05	0.000298	CcSEcCtD
Dantrolene—Rash—Gemcitabine—breast cancer	6.91e-05	0.000298	CcSEcCtD
Dantrolene—Dermatitis—Gemcitabine—breast cancer	6.9e-05	0.000298	CcSEcCtD
Dantrolene—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—breast cancer	6.89e-05	0.000951	CbGpPWpGaD
Dantrolene—Erythema—Methotrexate—breast cancer	6.87e-05	0.000296	CcSEcCtD
Dantrolene—Haemoglobin—Doxorubicin—breast cancer	6.87e-05	0.000296	CcSEcCtD
Dantrolene—Headache—Gemcitabine—breast cancer	6.87e-05	0.000296	CcSEcCtD
Dantrolene—CYP3A4—Tryptophan metabolism—CYP1A1—breast cancer	6.87e-05	0.000948	CbGpPWpGaD
Dantrolene—Musculoskeletal discomfort—Capecitabine—breast cancer	6.86e-05	0.000296	CcSEcCtD
Dantrolene—Flushing—Epirubicin—breast cancer	6.85e-05	0.000295	CcSEcCtD
Dantrolene—Vomiting—Fluorouracil—breast cancer	6.85e-05	0.000295	CcSEcCtD
Dantrolene—CYP3A4—Phase 1 - Functionalization of compounds—CYP2D6—breast cancer	6.85e-05	0.000946	CbGpPWpGaD
Dantrolene—Dyspepsia—Docetaxel—breast cancer	6.85e-05	0.000295	CcSEcCtD
Dantrolene—Haemorrhage—Doxorubicin—breast cancer	6.83e-05	0.000294	CcSEcCtD
Dantrolene—Hepatitis—Doxorubicin—breast cancer	6.83e-05	0.000294	CcSEcCtD
Dantrolene—Insomnia—Capecitabine—breast cancer	6.81e-05	0.000294	CcSEcCtD
Dantrolene—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—breast cancer	6.8e-05	0.000939	CbGpPWpGaD
Dantrolene—Rash—Fluorouracil—breast cancer	6.79e-05	0.000293	CcSEcCtD
Dantrolene—Dermatitis—Fluorouracil—breast cancer	6.79e-05	0.000293	CcSEcCtD
Dantrolene—Decreased appetite—Docetaxel—breast cancer	6.76e-05	0.000291	CcSEcCtD
Dantrolene—Hypersensitivity—Paclitaxel—breast cancer	6.76e-05	0.000291	CcSEcCtD
Dantrolene—Headache—Fluorouracil—breast cancer	6.75e-05	0.000291	CcSEcCtD
Dantrolene—CYP3A4—Biological oxidations—ALDH1A1—breast cancer	6.74e-05	0.00093	CbGpPWpGaD
Dantrolene—Dysgeusia—Methotrexate—breast cancer	6.73e-05	0.00029	CcSEcCtD
Dantrolene—CYP3A4—Phase 1 - Functionalization of compounds—NCOA2—breast cancer	6.72e-05	0.000928	CbGpPWpGaD
Dantrolene—Fatigue—Docetaxel—breast cancer	6.71e-05	0.000289	CcSEcCtD
Dantrolene—Nausea—Irinotecan—breast cancer	6.68e-05	0.000288	CcSEcCtD
Dantrolene—Nausea—Mitoxantrone—breast cancer	6.68e-05	0.000288	CcSEcCtD
Dantrolene—Constipation—Docetaxel—breast cancer	6.65e-05	0.000287	CcSEcCtD
Dantrolene—Pain—Docetaxel—breast cancer	6.65e-05	0.000287	CcSEcCtD
Dantrolene—Back pain—Methotrexate—breast cancer	6.64e-05	0.000286	CcSEcCtD
Dantrolene—Dyspepsia—Capecitabine—breast cancer	6.63e-05	0.000286	CcSEcCtD
Dantrolene—Chills—Epirubicin—breast cancer	6.63e-05	0.000286	CcSEcCtD
Dantrolene—Visual impairment—Doxorubicin—breast cancer	6.58e-05	0.000284	CcSEcCtD
Dantrolene—Asthenia—Paclitaxel—breast cancer	6.58e-05	0.000284	CcSEcCtD
Dantrolene—Decreased appetite—Capecitabine—breast cancer	6.55e-05	0.000282	CcSEcCtD
Dantrolene—Nausea—Gemcitabine—breast cancer	6.51e-05	0.000281	CcSEcCtD
Dantrolene—Fatigue—Capecitabine—breast cancer	6.49e-05	0.00028	CcSEcCtD
Dantrolene—Pruritus—Paclitaxel—breast cancer	6.49e-05	0.00028	CcSEcCtD
Dantrolene—Vision blurred—Methotrexate—breast cancer	6.47e-05	0.000279	CcSEcCtD
Dantrolene—Pain—Capecitabine—breast cancer	6.44e-05	0.000278	CcSEcCtD
Dantrolene—Constipation—Capecitabine—breast cancer	6.44e-05	0.000278	CcSEcCtD
Dantrolene—Erythema—Epirubicin—breast cancer	6.43e-05	0.000277	CcSEcCtD
Dantrolene—Feeling abnormal—Docetaxel—breast cancer	6.41e-05	0.000276	CcSEcCtD
Dantrolene—Nausea—Fluorouracil—breast cancer	6.4e-05	0.000276	CcSEcCtD
Dantrolene—Ill-defined disorder—Methotrexate—breast cancer	6.37e-05	0.000275	CcSEcCtD
Dantrolene—Gastrointestinal pain—Docetaxel—breast cancer	6.36e-05	0.000274	CcSEcCtD
Dantrolene—Anaemia—Methotrexate—breast cancer	6.35e-05	0.000274	CcSEcCtD
Dantrolene—Flushing—Doxorubicin—breast cancer	6.34e-05	0.000273	CcSEcCtD
Dantrolene—Tension—Epirubicin—breast cancer	6.31e-05	0.000272	CcSEcCtD
Dantrolene—Dysgeusia—Epirubicin—breast cancer	6.29e-05	0.000271	CcSEcCtD
Dantrolene—Diarrhoea—Paclitaxel—breast cancer	6.28e-05	0.000271	CcSEcCtD
Dantrolene—Nervousness—Epirubicin—breast cancer	6.24e-05	0.000269	CcSEcCtD
Dantrolene—Back pain—Epirubicin—breast cancer	6.22e-05	0.000268	CcSEcCtD
Dantrolene—Feeling abnormal—Capecitabine—breast cancer	6.21e-05	0.000267	CcSEcCtD
Dantrolene—Malaise—Methotrexate—breast cancer	6.19e-05	0.000267	CcSEcCtD
Dantrolene—Gastrointestinal pain—Capecitabine—breast cancer	6.16e-05	0.000265	CcSEcCtD
Dantrolene—Abdominal pain—Docetaxel—breast cancer	6.15e-05	0.000265	CcSEcCtD
Dantrolene—Body temperature increased—Docetaxel—breast cancer	6.15e-05	0.000265	CcSEcCtD
Dantrolene—Leukopenia—Methotrexate—breast cancer	6.15e-05	0.000265	CcSEcCtD
Dantrolene—Chills—Doxorubicin—breast cancer	6.13e-05	0.000264	CcSEcCtD
Dantrolene—Dizziness—Paclitaxel—breast cancer	6.07e-05	0.000262	CcSEcCtD
Dantrolene—Vision blurred—Epirubicin—breast cancer	6.06e-05	0.000261	CcSEcCtD
Dantrolene—CYP3A4—Biological oxidations—GSTA3—breast cancer	6e-05	0.000829	CbGpPWpGaD
Dantrolene—Urticaria—Capecitabine—breast cancer	5.98e-05	0.000258	CcSEcCtD
Dantrolene—Ill-defined disorder—Epirubicin—breast cancer	5.96e-05	0.000257	CcSEcCtD
Dantrolene—Abdominal pain—Capecitabine—breast cancer	5.95e-05	0.000257	CcSEcCtD
Dantrolene—Body temperature increased—Capecitabine—breast cancer	5.95e-05	0.000257	CcSEcCtD
Dantrolene—Convulsion—Methotrexate—breast cancer	5.95e-05	0.000257	CcSEcCtD
Dantrolene—Erythema—Doxorubicin—breast cancer	5.95e-05	0.000256	CcSEcCtD
Dantrolene—Anaemia—Epirubicin—breast cancer	5.94e-05	0.000256	CcSEcCtD
Dantrolene—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—breast cancer	5.94e-05	0.00082	CbGpPWpGaD
Dantrolene—CYP3A4—Metapathway biotransformation—GSTA3—breast cancer	5.92e-05	0.000818	CbGpPWpGaD
Dantrolene—Myalgia—Methotrexate—breast cancer	5.85e-05	0.000252	CcSEcCtD
Dantrolene—Tension—Doxorubicin—breast cancer	5.84e-05	0.000252	CcSEcCtD
Dantrolene—Vomiting—Paclitaxel—breast cancer	5.83e-05	0.000251	CcSEcCtD
Dantrolene—Dysgeusia—Doxorubicin—breast cancer	5.82e-05	0.000251	CcSEcCtD
Dantrolene—Malaise—Epirubicin—breast cancer	5.8e-05	0.00025	CcSEcCtD
Dantrolene—Rash—Paclitaxel—breast cancer	5.79e-05	0.000249	CcSEcCtD
Dantrolene—Dermatitis—Paclitaxel—breast cancer	5.78e-05	0.000249	CcSEcCtD
Dantrolene—Discomfort—Methotrexate—breast cancer	5.78e-05	0.000249	CcSEcCtD
Dantrolene—Nervousness—Doxorubicin—breast cancer	5.78e-05	0.000249	CcSEcCtD
Dantrolene—Leukopenia—Epirubicin—breast cancer	5.75e-05	0.000248	CcSEcCtD
Dantrolene—Back pain—Doxorubicin—breast cancer	5.75e-05	0.000248	CcSEcCtD
Dantrolene—Headache—Paclitaxel—breast cancer	5.75e-05	0.000248	CcSEcCtD
Dantrolene—Hypersensitivity—Docetaxel—breast cancer	5.73e-05	0.000247	CcSEcCtD
Dantrolene—CYP3A4—Phase 1 - Functionalization of compounds—NCOA1—breast cancer	5.66e-05	0.000782	CbGpPWpGaD
Dantrolene—Confusional state—Methotrexate—breast cancer	5.65e-05	0.000244	CcSEcCtD
Dantrolene—Anaphylactic shock—Methotrexate—breast cancer	5.61e-05	0.000242	CcSEcCtD
Dantrolene—Vision blurred—Doxorubicin—breast cancer	5.61e-05	0.000242	CcSEcCtD
Dantrolene—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—breast cancer	5.58e-05	0.000771	CbGpPWpGaD
Dantrolene—Asthenia—Docetaxel—breast cancer	5.58e-05	0.000241	CcSEcCtD
Dantrolene—Convulsion—Epirubicin—breast cancer	5.57e-05	0.00024	CcSEcCtD
Dantrolene—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—breast cancer	5.55e-05	0.000767	CbGpPWpGaD
Dantrolene—Hypertension—Epirubicin—breast cancer	5.55e-05	0.000239	CcSEcCtD
Dantrolene—Hypersensitivity—Capecitabine—breast cancer	5.55e-05	0.000239	CcSEcCtD
Dantrolene—Ill-defined disorder—Doxorubicin—breast cancer	5.52e-05	0.000238	CcSEcCtD
Dantrolene—Pruritus—Docetaxel—breast cancer	5.5e-05	0.000237	CcSEcCtD
Dantrolene—Anaemia—Doxorubicin—breast cancer	5.5e-05	0.000237	CcSEcCtD
Dantrolene—CYP3A4—Biological oxidations—GSTA4—breast cancer	5.49e-05	0.000758	CbGpPWpGaD
Dantrolene—Thrombocytopenia—Methotrexate—breast cancer	5.49e-05	0.000237	CcSEcCtD
Dantrolene—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—breast cancer	5.48e-05	0.000757	CbGpPWpGaD
Dantrolene—Myalgia—Epirubicin—breast cancer	5.47e-05	0.000236	CcSEcCtD
Dantrolene—Nausea—Paclitaxel—breast cancer	5.45e-05	0.000235	CcSEcCtD
Dantrolene—Hyperhidrosis—Methotrexate—breast cancer	5.42e-05	0.000234	CcSEcCtD
Dantrolene—CYP3A4—Metapathway biotransformation—GSTA4—breast cancer	5.42e-05	0.000748	CbGpPWpGaD
Dantrolene—Discomfort—Epirubicin—breast cancer	5.41e-05	0.000233	CcSEcCtD
Dantrolene—Asthenia—Capecitabine—breast cancer	5.4e-05	0.000233	CcSEcCtD
Dantrolene—Malaise—Doxorubicin—breast cancer	5.36e-05	0.000231	CcSEcCtD
Dantrolene—Dry mouth—Epirubicin—breast cancer	5.35e-05	0.000231	CcSEcCtD
Dantrolene—CYP3A4—Biological oxidations—GSTA2—breast cancer	5.35e-05	0.000739	CbGpPWpGaD
Dantrolene—Anorexia—Methotrexate—breast cancer	5.34e-05	0.00023	CcSEcCtD
Dantrolene—Pruritus—Capecitabine—breast cancer	5.33e-05	0.00023	CcSEcCtD
Dantrolene—Leukopenia—Doxorubicin—breast cancer	5.32e-05	0.000229	CcSEcCtD
Dantrolene—Diarrhoea—Docetaxel—breast cancer	5.32e-05	0.000229	CcSEcCtD
Dantrolene—Confusional state—Epirubicin—breast cancer	5.29e-05	0.000228	CcSEcCtD
Dantrolene—CYP3A4—Biological oxidations—SULT1A1—breast cancer	5.29e-05	0.00073	CbGpPWpGaD
Dantrolene—CYP3A4—Metapathway biotransformation—GPX2—breast cancer	5.28e-05	0.000729	CbGpPWpGaD
Dantrolene—Anaphylactic shock—Epirubicin—breast cancer	5.25e-05	0.000226	CcSEcCtD
Dantrolene—CYP3A4—Metapathway biotransformation—SULT1A1—breast cancer	5.21e-05	0.00072	CbGpPWpGaD
Dantrolene—CYP3A4—Metapathway biotransformation—GPX4—breast cancer	5.21e-05	0.00072	CbGpPWpGaD
Dantrolene—CYP3A4—Biological oxidations—GSTA1—breast cancer	5.16e-05	0.000713	CbGpPWpGaD
Dantrolene—Convulsion—Doxorubicin—breast cancer	5.15e-05	0.000222	CcSEcCtD
Dantrolene—Diarrhoea—Capecitabine—breast cancer	5.15e-05	0.000222	CcSEcCtD
Dantrolene—Dizziness—Docetaxel—breast cancer	5.14e-05	0.000222	CcSEcCtD
Dantrolene—Thrombocytopenia—Epirubicin—breast cancer	5.14e-05	0.000221	CcSEcCtD
Dantrolene—Hypertension—Doxorubicin—breast cancer	5.14e-05	0.000221	CcSEcCtD
Dantrolene—Tachycardia—Epirubicin—breast cancer	5.12e-05	0.000221	CcSEcCtD
Dantrolene—Musculoskeletal discomfort—Methotrexate—breast cancer	5.11e-05	0.00022	CcSEcCtD
Dantrolene—CYP3A4—Biological oxidations—NAT2—breast cancer	5.11e-05	0.000705	CbGpPWpGaD
Dantrolene—Hyperhidrosis—Epirubicin—breast cancer	5.07e-05	0.000219	CcSEcCtD
Dantrolene—Insomnia—Methotrexate—breast cancer	5.07e-05	0.000219	CcSEcCtD
Dantrolene—Myalgia—Doxorubicin—breast cancer	5.06e-05	0.000218	CcSEcCtD
Dantrolene—CYP3A4—Metapathway biotransformation—NAT2—breast cancer	5.04e-05	0.000695	CbGpPWpGaD
Dantrolene—Discomfort—Doxorubicin—breast cancer	5e-05	0.000216	CcSEcCtD
Dantrolene—Anorexia—Epirubicin—breast cancer	5e-05	0.000216	CcSEcCtD
Dantrolene—Somnolence—Methotrexate—breast cancer	4.98e-05	0.000215	CcSEcCtD
Dantrolene—Dizziness—Capecitabine—breast cancer	4.98e-05	0.000215	CcSEcCtD
Dantrolene—Dry mouth—Doxorubicin—breast cancer	4.95e-05	0.000213	CcSEcCtD
Dantrolene—Vomiting—Docetaxel—breast cancer	4.95e-05	0.000213	CcSEcCtD
Dantrolene—Dyspepsia—Methotrexate—breast cancer	4.93e-05	0.000213	CcSEcCtD
Dantrolene—Rash—Docetaxel—breast cancer	4.9e-05	0.000211	CcSEcCtD
Dantrolene—Dermatitis—Docetaxel—breast cancer	4.9e-05	0.000211	CcSEcCtD
Dantrolene—Confusional state—Doxorubicin—breast cancer	4.89e-05	0.000211	CcSEcCtD
Dantrolene—Decreased appetite—Methotrexate—breast cancer	4.87e-05	0.00021	CcSEcCtD
Dantrolene—Headache—Docetaxel—breast cancer	4.87e-05	0.00021	CcSEcCtD
Dantrolene—Anaphylactic shock—Doxorubicin—breast cancer	4.85e-05	0.000209	CcSEcCtD
Dantrolene—Fatigue—Methotrexate—breast cancer	4.83e-05	0.000208	CcSEcCtD
Dantrolene—Pain—Methotrexate—breast cancer	4.79e-05	0.000207	CcSEcCtD
Dantrolene—Vomiting—Capecitabine—breast cancer	4.79e-05	0.000206	CcSEcCtD
Dantrolene—Musculoskeletal discomfort—Epirubicin—breast cancer	4.78e-05	0.000206	CcSEcCtD
Dantrolene—Thrombocytopenia—Doxorubicin—breast cancer	4.75e-05	0.000205	CcSEcCtD
Dantrolene—Rash—Capecitabine—breast cancer	4.75e-05	0.000205	CcSEcCtD
Dantrolene—Insomnia—Epirubicin—breast cancer	4.74e-05	0.000205	CcSEcCtD
Dantrolene—Dermatitis—Capecitabine—breast cancer	4.74e-05	0.000204	CcSEcCtD
Dantrolene—Tachycardia—Doxorubicin—breast cancer	4.74e-05	0.000204	CcSEcCtD
Dantrolene—Headache—Capecitabine—breast cancer	4.72e-05	0.000203	CcSEcCtD
Dantrolene—Hyperhidrosis—Doxorubicin—breast cancer	4.69e-05	0.000202	CcSEcCtD
Dantrolene—Somnolence—Epirubicin—breast cancer	4.66e-05	0.000201	CcSEcCtD
Dantrolene—Anorexia—Doxorubicin—breast cancer	4.63e-05	0.000199	CcSEcCtD
Dantrolene—Nausea—Docetaxel—breast cancer	4.62e-05	0.000199	CcSEcCtD
Dantrolene—Feeling abnormal—Methotrexate—breast cancer	4.62e-05	0.000199	CcSEcCtD
Dantrolene—Dyspepsia—Epirubicin—breast cancer	4.62e-05	0.000199	CcSEcCtD
Dantrolene—Gastrointestinal pain—Methotrexate—breast cancer	4.58e-05	0.000198	CcSEcCtD
Dantrolene—Decreased appetite—Epirubicin—breast cancer	4.56e-05	0.000197	CcSEcCtD
Dantrolene—Fatigue—Epirubicin—breast cancer	4.52e-05	0.000195	CcSEcCtD
Dantrolene—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—breast cancer	4.5e-05	0.000622	CbGpPWpGaD
Dantrolene—Constipation—Epirubicin—breast cancer	4.49e-05	0.000193	CcSEcCtD
Dantrolene—Pain—Epirubicin—breast cancer	4.49e-05	0.000193	CcSEcCtD
Dantrolene—Nausea—Capecitabine—breast cancer	4.47e-05	0.000193	CcSEcCtD
Dantrolene—Urticaria—Methotrexate—breast cancer	4.45e-05	0.000192	CcSEcCtD
Dantrolene—Abdominal pain—Methotrexate—breast cancer	4.43e-05	0.000191	CcSEcCtD
Dantrolene—Body temperature increased—Methotrexate—breast cancer	4.43e-05	0.000191	CcSEcCtD
Dantrolene—Musculoskeletal discomfort—Doxorubicin—breast cancer	4.42e-05	0.000191	CcSEcCtD
Dantrolene—Insomnia—Doxorubicin—breast cancer	4.39e-05	0.000189	CcSEcCtD
Dantrolene—Feeling abnormal—Epirubicin—breast cancer	4.32e-05	0.000186	CcSEcCtD
Dantrolene—Somnolence—Doxorubicin—breast cancer	4.32e-05	0.000186	CcSEcCtD
Dantrolene—Gastrointestinal pain—Epirubicin—breast cancer	4.29e-05	0.000185	CcSEcCtD
Dantrolene—Dyspepsia—Doxorubicin—breast cancer	4.27e-05	0.000184	CcSEcCtD
Dantrolene—CYP3A4—Tryptophan metabolism—MDM2—breast cancer	4.24e-05	0.000585	CbGpPWpGaD
Dantrolene—Decreased appetite—Doxorubicin—breast cancer	4.22e-05	0.000182	CcSEcCtD
Dantrolene—Fatigue—Doxorubicin—breast cancer	4.19e-05	0.00018	CcSEcCtD
Dantrolene—Urticaria—Epirubicin—breast cancer	4.17e-05	0.00018	CcSEcCtD
Dantrolene—CYP3A4—Biological oxidations—MTR—breast cancer	4.16e-05	0.000575	CbGpPWpGaD
Dantrolene—Pain—Doxorubicin—breast cancer	4.15e-05	0.000179	CcSEcCtD
Dantrolene—Constipation—Doxorubicin—breast cancer	4.15e-05	0.000179	CcSEcCtD
Dantrolene—Abdominal pain—Epirubicin—breast cancer	4.15e-05	0.000179	CcSEcCtD
Dantrolene—Body temperature increased—Epirubicin—breast cancer	4.15e-05	0.000179	CcSEcCtD
Dantrolene—Hypersensitivity—Methotrexate—breast cancer	4.13e-05	0.000178	CcSEcCtD
Dantrolene—CYP3A4—Biological oxidations—HPGDS—breast cancer	4.08e-05	0.000564	CbGpPWpGaD
Dantrolene—Asthenia—Methotrexate—breast cancer	4.02e-05	0.000173	CcSEcCtD
Dantrolene—Feeling abnormal—Doxorubicin—breast cancer	4e-05	0.000172	CcSEcCtD
Dantrolene—Gastrointestinal pain—Doxorubicin—breast cancer	3.97e-05	0.000171	CcSEcCtD
Dantrolene—Pruritus—Methotrexate—breast cancer	3.97e-05	0.000171	CcSEcCtD
Dantrolene—CYP3A4—Biological oxidations—GSTT1—breast cancer	3.96e-05	0.000547	CbGpPWpGaD
Dantrolene—Hypersensitivity—Epirubicin—breast cancer	3.87e-05	0.000167	CcSEcCtD
Dantrolene—Urticaria—Doxorubicin—breast cancer	3.86e-05	0.000166	CcSEcCtD
Dantrolene—Body temperature increased—Doxorubicin—breast cancer	3.84e-05	0.000165	CcSEcCtD
Dantrolene—Abdominal pain—Doxorubicin—breast cancer	3.84e-05	0.000165	CcSEcCtD
Dantrolene—Diarrhoea—Methotrexate—breast cancer	3.84e-05	0.000165	CcSEcCtD
Dantrolene—Asthenia—Epirubicin—breast cancer	3.76e-05	0.000162	CcSEcCtD
Dantrolene—CYP3A4—Biological oxidations—CYP17A1—breast cancer	3.75e-05	0.000518	CbGpPWpGaD
Dantrolene—Pruritus—Epirubicin—breast cancer	3.71e-05	0.00016	CcSEcCtD
Dantrolene—CYP3A4—Biological oxidations—PTGS1—breast cancer	3.71e-05	0.000512	CbGpPWpGaD
Dantrolene—Dizziness—Methotrexate—breast cancer	3.71e-05	0.00016	CcSEcCtD
Dantrolene—CYP3A4—Metapathway biotransformation—CYP17A1—breast cancer	3.7e-05	0.00051	CbGpPWpGaD
Dantrolene—CYP3A4—Biological oxidations—CYP2D6—breast cancer	3.64e-05	0.000502	CbGpPWpGaD
Dantrolene—Diarrhoea—Epirubicin—breast cancer	3.59e-05	0.000155	CcSEcCtD
Dantrolene—CYP3A4—Metapathway biotransformation—CYP2D6—breast cancer	3.59e-05	0.000496	CbGpPWpGaD
Dantrolene—Hypersensitivity—Doxorubicin—breast cancer	3.58e-05	0.000154	CcSEcCtD
Dantrolene—CYP3A4—Biological oxidations—NCOA2—breast cancer	3.57e-05	0.000493	CbGpPWpGaD
Dantrolene—Vomiting—Methotrexate—breast cancer	3.56e-05	0.000154	CcSEcCtD
Dantrolene—Rash—Methotrexate—breast cancer	3.53e-05	0.000152	CcSEcCtD
Dantrolene—Dermatitis—Methotrexate—breast cancer	3.53e-05	0.000152	CcSEcCtD
Dantrolene—Headache—Methotrexate—breast cancer	3.51e-05	0.000151	CcSEcCtD
Dantrolene—Asthenia—Doxorubicin—breast cancer	3.48e-05	0.00015	CcSEcCtD
Dantrolene—Dizziness—Epirubicin—breast cancer	3.47e-05	0.00015	CcSEcCtD
Dantrolene—Pruritus—Doxorubicin—breast cancer	3.43e-05	0.000148	CcSEcCtD
Dantrolene—Vomiting—Epirubicin—breast cancer	3.34e-05	0.000144	CcSEcCtD
Dantrolene—Nausea—Methotrexate—breast cancer	3.33e-05	0.000144	CcSEcCtD
Dantrolene—Diarrhoea—Doxorubicin—breast cancer	3.32e-05	0.000143	CcSEcCtD
Dantrolene—Rash—Epirubicin—breast cancer	3.31e-05	0.000143	CcSEcCtD
Dantrolene—Dermatitis—Epirubicin—breast cancer	3.3e-05	0.000142	CcSEcCtD
Dantrolene—Headache—Epirubicin—breast cancer	3.29e-05	0.000142	CcSEcCtD
Dantrolene—Dizziness—Doxorubicin—breast cancer	3.21e-05	0.000138	CcSEcCtD
Dantrolene—CYP3A4—Biological oxidations—CYP1B1—breast cancer	3.15e-05	0.000436	CbGpPWpGaD
Dantrolene—Nausea—Epirubicin—breast cancer	3.12e-05	0.000134	CcSEcCtD
Dantrolene—CYP3A4—Metapathway biotransformation—CYP1B1—breast cancer	3.11e-05	0.00043	CbGpPWpGaD
Dantrolene—Vomiting—Doxorubicin—breast cancer	3.09e-05	0.000133	CcSEcCtD
Dantrolene—Rash—Doxorubicin—breast cancer	3.06e-05	0.000132	CcSEcCtD
Dantrolene—Dermatitis—Doxorubicin—breast cancer	3.06e-05	0.000132	CcSEcCtD
Dantrolene—Headache—Doxorubicin—breast cancer	3.04e-05	0.000131	CcSEcCtD
Dantrolene—CYP3A4—Biological oxidations—NCOA1—breast cancer	3.01e-05	0.000416	CbGpPWpGaD
Dantrolene—CYP3A4—Biological oxidations—CYP19A1—breast cancer	2.97e-05	0.00041	CbGpPWpGaD
Dantrolene—CYP3A4—Metapathway biotransformation—CYP19A1—breast cancer	2.92e-05	0.000404	CbGpPWpGaD
Dantrolene—Nausea—Doxorubicin—breast cancer	2.88e-05	0.000124	CcSEcCtD
Dantrolene—CYP3A4—Biological oxidations—COMT—breast cancer	2.76e-05	0.000381	CbGpPWpGaD
Dantrolene—CYP3A4—Biological oxidations—GSTP1—breast cancer	2.74e-05	0.000379	CbGpPWpGaD
Dantrolene—CYP3A4—Metapathway biotransformation—COMT—breast cancer	2.72e-05	0.000376	CbGpPWpGaD
Dantrolene—CYP3A4—Metapathway biotransformation—GSTP1—breast cancer	2.71e-05	0.000374	CbGpPWpGaD
Dantrolene—CYP3A4—Biological oxidations—GSTM1—breast cancer	2.52e-05	0.000348	CbGpPWpGaD
Dantrolene—CYP3A4—Metapathway biotransformation—GSTM1—breast cancer	2.49e-05	0.000343	CbGpPWpGaD
Dantrolene—CYP3A4—Biological oxidations—CYP1A1—breast cancer	2.39e-05	0.00033	CbGpPWpGaD
Dantrolene—CYP3A4—Metapathway biotransformation—CYP1A1—breast cancer	2.36e-05	0.000326	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—SYNJ2—breast cancer	1.92e-05	0.000266	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—NDUFS3—breast cancer	1.79e-05	0.000247	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—CHST9—breast cancer	1.68e-05	0.000232	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—COX11—breast cancer	1.59e-05	0.00022	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—SHMT1—breast cancer	1.46e-05	0.000201	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—CDA—breast cancer	1.46e-05	0.000201	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—SLCO1B1—breast cancer	1.4e-05	0.000194	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—SLC2A5—breast cancer	1.4e-05	0.000194	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—APRT—breast cancer	1.35e-05	0.000187	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—ANGPTL4—breast cancer	1.27e-05	0.000176	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—ESRRA—breast cancer	1.27e-05	0.000176	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—GPI—breast cancer	1.21e-05	0.000167	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—HADHB—breast cancer	1.21e-05	0.000167	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—ALDH7A1—breast cancer	1.15e-05	0.000159	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—ALDH1A1—breast cancer	1.15e-05	0.000159	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—FHL2—breast cancer	1.1e-05	0.000153	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—ADSL—breast cancer	1.1e-05	0.000153	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—NME1—breast cancer	1.1e-05	0.000153	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—UMPS—breast cancer	1.1e-05	0.000153	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—PHGDH—breast cancer	1.1e-05	0.000153	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—BRIP1—breast cancer	1.08e-05	0.00015	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—HPSE—breast cancer	1.08e-05	0.00015	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—LDHB—breast cancer	1.08e-05	0.00015	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—GSTA3—breast cancer	1.03e-05	0.000142	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—ABCC1—breast cancer	1.03e-05	0.000142	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—HMMR—breast cancer	1.03e-05	0.000142	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—PPARGC1B—breast cancer	9.95e-06	0.000137	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—GSTA4—breast cancer	9.39e-06	0.00013	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—CA9—breast cancer	9.39e-06	0.00013	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—GSTA2—breast cancer	9.15e-06	0.000126	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—GPX2—breast cancer	9.15e-06	0.000126	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—GPX4—breast cancer	9.04e-06	0.000125	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—SULT1A1—breast cancer	9.04e-06	0.000125	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—IDH1—breast cancer	8.83e-06	0.000122	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—GSTA1—breast cancer	8.83e-06	0.000122	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—NAT2—breast cancer	8.73e-06	0.000121	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—DPYD—breast cancer	7.66e-06	0.000106	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—MED12—breast cancer	7.66e-06	0.000106	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—ALDOA—breast cancer	7.54e-06	0.000104	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—NCOA3—breast cancer	7.32e-06	0.000101	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—SLC2A2—breast cancer	7.27e-06	0.0001	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—ABCG2—breast cancer	7.12e-06	9.83e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—CPT1A—breast cancer	7.12e-06	9.83e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—MTR—breast cancer	7.12e-06	9.83e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—HPGDS—breast cancer	6.98e-06	9.64e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—HBA1—breast cancer	6.94e-06	9.58e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—ACHE—breast cancer	6.77e-06	9.35e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—GSTT1—breast cancer	6.77e-06	9.35e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—CYP17A1—breast cancer	6.41e-06	8.85e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—ENO1—breast cancer	6.34e-06	8.76e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—PTGS1—breast cancer	6.34e-06	8.76e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—CYP2D6—breast cancer	6.22e-06	8.59e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—NCOA2—breast cancer	6.11e-06	8.43e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—FASN—breast cancer	5.92e-06	8.18e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—BCHE—breast cancer	5.9e-06	8.15e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—SLC5A5—breast cancer	5.83e-06	8.05e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—NQO1—breast cancer	5.63e-06	7.77e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—SLC2A1—breast cancer	5.63e-06	7.77e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—CYP1B1—breast cancer	5.39e-06	7.45e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—HSP90AA1—breast cancer	5.29e-06	7.31e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—NCOA1—breast cancer	5.15e-06	7.11e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—STK11—breast cancer	5.07e-06	7e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—CYP19A1—breast cancer	5.07e-06	7e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—COMT—breast cancer	4.72e-06	6.51e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—GSTP1—breast cancer	4.69e-06	6.48e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—HMOX1—breast cancer	4.63e-06	6.39e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—ITPR1—breast cancer	4.62e-06	6.38e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—ABCB1—breast cancer	4.44e-06	6.13e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—TYMS—breast cancer	4.36e-06	6.03e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—GSTM1—breast cancer	4.31e-06	5.96e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—PLA2G4A—breast cancer	4.31e-06	5.96e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—NCOR1—breast cancer	4.31e-06	5.96e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—GPX1—breast cancer	4.13e-06	5.7e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—CYP1A1—breast cancer	4.09e-06	5.65e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—ERCC2—breast cancer	4.05e-06	5.6e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—MTHFR—breast cancer	3.81e-06	5.26e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—CAV1—breast cancer	3.52e-06	4.85e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—PIK3CG—breast cancer	3.2e-06	4.42e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—PIK3CD—breast cancer	2.81e-06	3.89e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—ALB—breast cancer	2.78e-06	3.84e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—NOS3—breast cancer	2.66e-06	3.67e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—PIK3CB—breast cancer	2.45e-06	3.39e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—PTGS2—breast cancer	2.43e-06	3.36e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—PTEN—breast cancer	2.12e-06	2.93e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—PIK3CA—breast cancer	1.5e-06	2.07e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—AKT1—breast cancer	1.22e-06	1.69e-05	CbGpPWpGaD
